7 completed, 2 withdrawn, 1 not yet recruiting, 1 recruiting. 11 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Completed 7, Withdrawn 2, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 3 | Completed 2, Not yet recruiting 1 |
Follow FOLFOX regimen: new trials by email Literature Review of FOLFOX regimen trials Research Report on FOLFOX regimen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma FOLFOX regimen, Immunotherapy, targeted therapy - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | BinYong Liang | 100 | 2026-04-30 | 2026-04-13 |
| A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies M3T01, Pembrolizumab, Chemoradiation - Advanced Solid Tumors | Phase 1 | Recruiting | Providence Health & Services | 110 | 2025-06-17 | 2026-07-23 |
| Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy Regorafenib, Nivolumab, CapeOX - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 1 / Phase 2 | Completed | National Cancer Center Hospital East | 30 | 2022-06-06 | 2026-04-09 |
| A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma Entinostat, FOLFOX regimen - Pancreas Cancer | Phase 1 | Withdrawn | Abramson Cancer Center at Penn Medicine | 2021-01-01 | 2021-01-15 | |
| Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy FOLFOX regimen, Nivolumab, Ipilimumab - Colorectal Cancer Metastatic | Phase 1 | Withdrawn | Gustave Roussy, Cancer Campus, Grand Paris | 2019-06-04 | 2020-02-17 | |
| A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer ompenaclid, FOLFIRI, Bevacizumab - Gastrointestinal Cancer, Gastrointestinal Neoplasms | Phase 1 | Completed | Inspirna, Inc. | 89 | 2018-06-05 | 2025-04-03 |
| Lidocaine for Oxaliplatin-induced Neuropathy Lidocaine Hydrochloride, Placebo, FOLFOX regimen - Neuropathy, Painful, Chemotherapy-induced Peripheral Neuropathy | Phase 1 / Phase 2 | Completed | Washington University School of Medicine | 26 | 2017-09-15 | 2022-03-09 |
| A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer FOLFOX regimen, bevacizumab, dulanermin - Metastatic Colorectal Cancer | Phase 1 | Completed | Genentech, Inc. | 23 | 2009-05-01 | 2016-11-02 |
| Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer bevacizumab, FOLFOX regimen, fluorouracil - Colorectal Cancer | Phase 1 | Completed | City of Hope Medical Center | 11 | 2009-03-11 | 2025-06-22 |
| Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer FOLFOX regimen, dexamethasone, floxuridine - Colorectal Cancer, Metastatic Cancer | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 38 | 2003-01-01 | 2025-03-26 |
| Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer FOLFOX regimen, dexamethasone, floxuridine - Colorectal Cancer, Metastatic Cancer | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 2000-08-01 | 2013-01-18 |
Colorectal Neoplasms (6) · Colonic Neoplasms (4) · Rectal Neoplasms (3) · Neoplasm Metastasis (2) · Adenocarcinoma Of Esophagus (1) · Carcinoma, Hepatocellular (1) · Cold Hypersensitivity (1) · Gastrointestinal Neoplasms (1) · Neuralgia (1) · Neuropathy, Painful (1) · Pancreatic Neoplasms (1) · Stomach Neoplasms (1)
Memorial Sloan Kettering Cancer Center (2) · Abramson Cancer Center at Penn Medicine (1) · BinYong Liang (1) · City of Hope Medical Center (1) · Genentech, Inc. (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Inspirna, Inc. (1) · National Cancer Center Hospital East (1) · Providence Health & Services (1) · Washington University School of Medicine (1)
United States (7) · France (1) · Japan (1)
Nancy E. Kemeny, MD (2) · Chia Portera, M.D. (1) · Kohei Shitara, MD (1) · Lily L. Lai, MD (1) · Robert Wasserman, MD (1) · Rom Leidner, MD (1) · Simon Haroutounian, PhD (1)
PMID 16009951, PMID 19233901, PMID 26032776, PMID 39863139
2017 (1), P30CA008748 (1), P30CA033572 (1)